VivoSim Announces Pricing of up to a $4 Million Public Offering
VivoSim Labs, a Nasdaq-listed biotech company specializing in next-generation New Approach Methodologies (NAMs) for preclinical safety testing using 3D human tissue models, has announced the pricing of a $4 million public offering. The offering comprises an initial $3 million closing and an additional $1 million tranche contingent on conditions suc…